Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock ...

Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.

In the latest trading session, Eli Lilly (LLY) closed at $763.57, marking a +2.06% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.13%. Meanwhile, the Dow ...

Eli Lilly and Company LLY announced plans to spend $5 billion to build a massive new manufacturing facility in Virginia as ...

AbbVie ABBV has gained 22.5% so far this year against a decrease of 0.1% for the industry. The stock has also outperformed ...

Eli Lilly and Company has recently surpassed a significant technical benchmark, reclaiming the 50-day moving average, ...

Eli Lilly and Company recently saw its stock price climb +1.51%, reaching $738.17, and surpassing the S&P 500's modest gain ...

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Pharmaceutical giant Eli Lilly expanded its Virginia facility investment plans to $5 billion from original $2.1 billion amid ...

Eli Lilly (LLY) stock is in focus as its popular GLP-1 med Mounjaro hits main goals in a Phase 3 trial for children and ...

A hopeful report about a potential blockbuster drug currently in development and news of an expansion of manufacturing ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...